Tools & Calculators
Minimum Investment
TBA
TBA
TBA
TBA
TBA
TBA
TBA
TBA
Gaudium IVF and Women Health Limited was founded to fulfill the dreams of motherhood. As one of India’s leading IVF centres, it has brought happiness to thousands of families worldwide. The name “Gaudium,” meaning joy, reflects its commitment to affordable and effective fertility care. Recognized as a top IVF centre, it combines advanced reproductive technology with experienced specialists to provide personalized treatment. With numerous accolades and global recognition, Gaudium remains dedicated to offering world-class fertility solutions, ensuring every patient receives compassionate and expert care.
Explore our comprehensive IPO pages to stay updated on the latest trends and insights.

Gaudium IVF and Women Health Limited prioritizes personalized care, recognizing the uniqueness of each patient. With dedicated counsellors, the company provides emotional support and guidance throughout the parenthood journey. Patients benefit from quality consultations, confidentiality, transparency, and unwavering assistance during their IVF treatment.
Founded by Dr. Manika Khanna and Dr. Peeyush Khanna, Gaudium IVF brings over two decades of infertility expertise. The Gaudium IVF Foundation, established in 2014, extends healthcare support to underprivileged communities. Expert gynaecologists and embryologists ensure meticulous and compassionate IVF procedures.
Gaudium IVF integrates cutting-edge technology to deliver world-class fertility treatments. The use of INTEGRA Ti™ for ICSI procedures, advanced egg quality assessment tools, Samsung Ultrasound Machines, and sterile operating rooms enhances precision and patient safety.
Gaudium IVF is equipped to manage complex fertility cases using advanced diagnostic techniques, including hysterosalpingography (HSG), transvaginal scans, follicular monitoring, ultrasound-guided biopsies, transrectal ultrasounds, and ovarian cyst aspiration.
Gaudium IVF offers tailored payment plans, allowing patients to choose between lump sum payments or convenient instalments based on their financial preferences. These flexible options ensure affordability without compromising treatment quality.
Gaudium IVF operates an efficient, asset-light model with standardized protocols and internal controls. This approach minimizes dependency on individual practitioners, ensuring scalable, high-quality reproductive care across multiple locations.
With central hubs in Mumbai, Bangalore, Delhi NCR, and Patna, Gaudium IVF provides advanced fertility treatments, including IVF, IUI, embryo freezing, and embryo transfer. These hubs serve as centres of excellence, catering to wider geographic areas.
Gaudium IVF extends its reach through smaller spoke centres around central hubs, improving accessibility to consultations, initial treatments, and follow-ups. Patients requiring advanced care are referred to nearby hubs, ensuring seamless, high-quality reproductive health services.
Gaudium IVF and Women Health Limited, incorporated in 2015, is a leading provider of IVF (In Vitro Fertilization) treatment in India. Operating on a hub-and-spoke model, the company has expanded across multiple states, offering comprehensive fertility care.
Founder and Expertise
Founded by Dr. Manika Khanna, a specialist trained in gynecological endoscopic surgery from Kiel, Germany, and Gynaec Endoscopy from Melbourne IVF Gujarat Private Limited, the company is committed to providing advanced fertility treatments.
PAN-India Presence
Global Reach
Gaudium IVF serves patients from various countries, including:
Additional Services
Achievements and Recognition
International Collaboration
In May 2024, Gaudium IVF entered a collaboration agreement with a company in London to provide IVF consultancy and guidance, acting as the company’s exclusive representative in the region.
With a commitment to innovation, patient care, and expanding fertility services globally, Gaudium IVF continues to be a trusted name in reproductive health.
IVF Market in India
Growth Drivers
Gaudium IVF and Women Health has filed a Draft Red Herring Prospectus (DRHP) with SEBI for its IPO. The book-built issue includes a fresh issue of ₹1.83 crore equity shares and an offer for sale of 183,544 shares. The IPO will be listed on NSE and BSE, with allocations of 35% for retail investors, 50% for QIBs, and 15% for HNIs. Dr. Manika Khanna is selling shares in the OFS. Sarthi Capital Advisors is the lead manager, and Bigshare Services is the registrar.
| Category | Details |
| Issue Type | Book Built Issue IPO |
| Total Issue Size | Fresh Issue: 1.89 crore shares
Offer for Sale (OFS): 0.25 crore shares |
| IPO Dates | TBA |
| Price Bands | TBA |
| Lot Size | TBA |
| Face Value | ₹5 per share |
| Listing Exchange | BSE, NSE |
| Shareholding pre-issue | TBA |
| Shareholding post -issue | TBA |
| IPO Activity | Date |
| IPO Open Date | TBA |
| IPO Close Date | TBA |
| Basis of Allotment Date | TBA |
| Refunds Initiation | TBA |
| Credit of Shares to Demat | TBA |
| IPO Listing Date | TBA |
| Application | Lots | Shares | Amount |
| Retail (Min) | TBA | TBA | TBA |
| Retail (Max) | TBA | TBA | TBA |
| S-HNI (Min) | TBA | TBA | TBA |
| S-HNI (Max) | TBA | TBA | TBA |
| B-HNI (Min) | TBA | TBA | TBA |
| KPI | Value |
| Earnings Per Share (EPS) | 2.70 |
| Price/Earnings (P/E) Ratio | TBD |
| Return on Net Worth (RoNW) | 61% |
| Net Asset Value (NAV) | 335.98 |
| Return on Equity | 49.90% |
| Return on Capital Employed (ROCE) | 46.27% |
| EBITDA Margin | 48.28% |
| PAT Margin | 30.89% |
| Debt to Equity Ratio | 0.69 |
Objectives of the IPO Proceeds
The Net Proceeds are intended to be utilised as per the details provided in the table below:
| Particulars | Amount (in ₹ lakhs) |
| Funding capital expenditure towards establishment of New IVF Centers of our Company | 9469.92 |
| Funding working capital requirements for establishment of New IVF Centres Investment in the Subsidiary, EKK Global Private Limited for
a) Launching of FMCG products; and b) Funding its Working Capital Requirements |
395.23
292.25 2207.75 |
| General corporate purposes* | [●] |
Note: *To be determined upon finalisation of the Offer Price and updated in the Prospectus prior to filing with the RoC
| Particulars | 30 Sept 2024 | 31 Mar 2024 | 31 Mar 2023 | 31 Mar 2022 |
| Assets | 7227.02 | 5729.28 | 3662.75 | 1777.08 |
| Revenue | 3169.12 | 5348.46 | 4423.69 | 3651.98 |
| Profit After Tax | 814.41 | 1660.12 | 1352.46 | 882.82 |
| Reserves and Surplus | 1085.18 | 3227.94 | 217.86 | 830.40 |
| Total Borrowings | 1947.93 | 1572.58 | 978.11 | 594.82 |
| Total Liabilities | 3072.12 | 2402.32 | 1389.87 | 847.66 |
Gaudium IVF and Women Health Limited is committed to expanding its services beyond core IVF treatments. The company aims to strengthen its presence across India using a Hub-and-Spoke model, ensuring greater accessibility to high-quality reproductive care in underserved regions. Additionally, it is diversifying into the FMCG sector through its wholly owned subsidiary, EKK Global Private Limited, introducing specialized healthcare products.
Gaudium IVF is expanding its network using a Hub-and-Spoke model, improving IVF accessibility in underserved regions. This approach ensures consistent service quality, centralizes advanced procedures at hubs, optimizes resources, and strengthens patient referrals within the Gaudium IVF network for better reproductive care.
Leveraging its extensive network of patients, clinics, and healthcare professionals, Gaudium IVF is entering the FMCG sector. Through its subsidiary, EKK Global Private Limited, the company will introduce specialized mother-and-child wellness products and nutraceuticals aimed at supporting maternal health and managing diabetes.
Follow these simple steps to apply for an IPO through HDFC SKY. Secure your investments and explore new opportunities with ease by accessing the IPOs available on the platform.
1Login to your HDFC SKY Account
2Select Issue
3Enter Number of Lots and your Price.
4Enter UPI ID
5Complete Transaction on Your UPI App
The IPO is anticipated to open in mid-May 2025.
Investors can apply online using UPI or ASBA through their bank’s net banking services.
Retail investors are allocated 35% of the total shares in the IPO.
Each share in the IPO has a face value of ₹5.
The shares are expected to be listed on the BSE and NSE in mid-May 2025.